Skip to content
Fear and GreedStocks35Crypto24
Start for free

PTC Therapeutics stock

PTCTNASDAQ

PTC Therapeutics, Inc., HealthcareISIN US69366J2006

$63.36▼ $1.55 (−2.4%)Closing price of 12 Nov 2026

48Score 48 out of 100, Weak

Turn on early warning

Price and trend

61 / 100

Price history

−15% in one year

The chart shows daily closes over 13 years, adjusted for stock splits and without dividends. Click into the chart to set a price alert at that price.

Long-term trend

Below the 200-day line: the price is 9.8% below it.

Trend change

Since September 2026 the 50-day line has been below the 200-day line; the trend has turned down.

Momentum

Normal: the price is neither overheated nor sold off (RSI 56).

Distance to the high

The price is 29% below its 52-week high. Largest decline in 13 years: 95% (March 2015 to November 2016).

Chart figures for advanced users
SMA 50$64.28
Average price of the last 50 trading days, shows the short-term trend.
SMA 200$70.23
Average price of the last 200 trading days, shows the long-term trend.
RSI (14)56
Relative strength over the last 14 days on a scale from 0 to 100. Above 70 the price counts as overheated, below 30 as sharply fallen.
MACDabove the signal line
Compares a fast and a slow price average. Above its signal line momentum is rising, below it momentum is fading.
Support$59.24
The lowest closing price of the last twelve months.
Resistance$89.55
The highest closing price of the last twelve months.
What would $1,000 in PTC Therapeutics have become?Return triangle for PTC Therapeutics
Market cap
$5.42B
Div. yield
no dividend
Loss
26.7
on earnings for the next twelve months ($2.43 per share)
Fair value
$94.06

Snapshot

Computed from the data by fixed rules, no AI

  • PTC Therapeutics, Inc. belongs to the Biotechnology industry (United States) and, with a market value of $5.29B, is number 71 of 296 companies in its industry on MEQIRI.
  • For fiscal 2026, analysts expect on average revenue of $1.32B (down 23.7%) and adjusted earnings per share of $0.53 (down 93.2%).
  • MEQIRI Score 48 out of 100 (Weak): rank 408 of 714 in Healthcare, median 53.
Show more
  • Our model puts fair value at $94.06, with the price 31% below it.

In plain words

The numbers on this page in plain words, written by an AI

Strengths

  • High return on capitalReturn on invested capital 212.6% in fiscal 2025, Biotechnology median −24.3%.
  • Growing faster than its industryRevenue up 35.4% a year since 2020, Biotechnology median 19.7%.Growth 70

Weaknesses

  • Loss-makingLoss of $105.97M over the last 12 months.Fundamentals 24
  • DilutionShare count up 20% since 2020.Capital allocation 27
  • Negative free cash flowFree cash flow −$37.96M over the last 12 months.Fundamentals 24
48/ 100
MEQIRI Score
Weak

Its standout strength is growth, while capital allocation and fundamentals hold the score back.

Daily figure as of 12 Nov 2026

How the score is calculated

Score overview

Score since yesterday from 46 to 48.

Fundamental quality fluctuates.

Profit consistency10% of years
Cash conversion (free cash flow to earnings, 12 months)not measured
ROIC (12 months)4.8%
Positive free cash flow10% of years
How this category is measured

Score history

The full history of up to 20 years comes with MEQIRI Pro.

See plans

Crash risk high

How well MEQIRI warns

One of the 30% with the highest crash risk among smaller stocks.

From 2016 to 2025, 36 in 100 such stocks fell 30% or more within a year, against a group average of 23 in 100.

What drives the risk

  • weak fundamentals

Valuation

Valuation signal

Possible value trap
Price
$64.91
Fair value
$94.06
Gap to fair value
−31%

Closing price of 11 Nov 2026, used by the daily score.

In our model the price counts as cheap below $67.19 and expensive above $156.77 (uncertainty high, based on the price swings of the past year).

Calculated with a cost of equity of 9.7%. At 10.7% the fair value would be $80.55, at 8.7% it would be $113.08.

Possible value trap: looks cheap, but score below 50, weak balance sheet.

Valuation metrics

no data
34.4
Fair value (model)
$94.06

From the cash-flow model alone; without earnings there is no industry value.

Calculate with your own assumptions

Company performance

This shows several years of history with an automatic assessment.

Revenue

15 years

In the twelve months to 30 Sep 2026, revenue fell 35.1% on the twelve months before. Revenue has grown strongly since 2011, at around 23% per year.

Margins

15 years
  • Gross margin
  • Operating margin
  • Net margin

In fiscal 2025: gross 96%, operating 49%, net 39%. Last 12 months: net −9%.

Debt & balance sheet

Fiscal 2025
−13.19
5.6x
2.35
Cash & equivalents
$1.95B

Debt is elevated. Keep an eye on the interest burden and refinancing.

Earnings

Next earnings
18 Feb 2027in 98 days
Last reported
29 Oct 2026EPS reported −$0.62 (expected $0.14)below expectations

Analyst estimates

Analysts have cut their 2026 earnings estimate by 57.1% since 15 Oct 2026. Falling estimates often precede bad news.

Fiscal 202610 analysts
Earnings per share
$0.53−57.1%
Revenue
$1.32B+5.1%
Fiscal 202710 analysts
Earnings per share
$2.73+10.1%
Revenue
$1.43B+4.2%

MEQIRI has stored the estimates since 15 Oct 2026. Until 30 days are available, the card shows the change since that day. Mean estimate according to Financial Modeling Prep. No price target and no recommendation.

Company outlook raised

Share price after the results: +10.7%

2026 product revenue guidance raised to $750 million to $850 million, total revenue of $1.08 billion to $1.18 billion.

Supporting passage from the call, verbatim
“With this revenue performance, we are raising our 2026 full-year product revenue guidance to $750 million to $850 million, with expected total revenue of $1.08 billion to $1.18 billion.”

The outlook is not part of the score and not a recommendation to buy or sell.

From the earnings call on 7 May 2026 (fiscal Q1 2026), read by AI.

Insiders

Open-market purchases and sales by executives, board members and major holders

All insider purchases

No open-market purchases in the last 6 months. 9 insiders sold, $23.58M in total.

Sales say less than purchases: many insiders sell on a fixed plan, for taxes or to diversify.

  • Schmertzler MichaelSale

    14 Oct 2026, Board

    Shares
    2,500
    Price
    $59.61
    Value
    $149,037
  • Boulding Mark ElliottSale

    9 Oct 2026, EXEC. VP AND CLO

    Shares
    192
    Price
    $64.26
    Value
    $12,338
  • Schmertzler MichaelSale

    7 Oct 2026, Board

    Shares
    2,500
    Price
    $63.39
    Value
    $158,480
Show 28 more
  • Boulding Mark ElliottSale

    6 Oct 2026, EXEC. VP AND CLO

    Shares
    435
    Price
    $64.16
    Value
    $27,910
  • Boulding Mark ElliottSale

    5 Oct 2026, EXEC. VP AND CLO

    Shares
    1,638
    Price
    $64.03
    Value
    $104,881
  • Steele Glenn Jr Md PhdSale

    30 Sept 2026, Board

    Shares
    12,000
    Price
    $65.16
    Value
    $781,920
  • Schmertzler MichaelSale

    17 Sept 2026, Board

    Shares
    10,000
    Price
    $67.85
    Value
    $678,533
  • Schmertzler MichaelSale

    16 Sept 2026, Board

    Shares
    10,000
    Price
    $67.12
    Value
    $671,195
  • Schmertzler MichaelSale

    10 Sept 2026, Board

    Shares
    10,000
    Price
    $67.34
    Value
    $673,400
  • Schmertzler MichaelSale

    9 Sept 2026, Board

    Shares
    10,000
    Price
    $67.84
    Value
    $678,403
  • Schmertzler MichaelSale

    27 Aug 2026, Board

    Shares
    12,500
    Price
    $71.58
    Value
    $894,784
  • Schmertzler MichaelSale

    26 Aug 2026, Board

    Shares
    12,500
    Price
    $72.94
    Value
    $911,725
  • Schmertzler MichaelSale

    20 Aug 2026, Board

    Shares
    12,500
    Price
    $71.11
    Value
    $888,858
  • Schmertzler MichaelSale

    19 Aug 2026, Board

    Shares
    12,500
    Price
    $73.32
    Value
    $916,554
  • Boulding Mark ElliottSale

    17 Aug 2026, EXEC. VP AND CLO

    Shares
    2,813
    Price
    $72.57
    Value
    $204,127
  • Klein Matthew B.Sale

    4 Aug 2026, CHIEF EXECUTIVE OFFICER

    Shares
    10,292
    Price
    $68.57
    Value
    $705,722
  • Gravier PierreSale

    14 Jul 2026, CHIEF FINANCIAL OFFICER

    Shares
    3,494
    Price
    $80.35
    Value
    $280,743
  • Smith Mary L.Sale

    9 Jul 2026, Board

    Shares
    5,834
    Price
    $90.00
    Value
    $525,060
  • Almstead Neil GregorySale

    9 Jul 2026, CHIEF TECHNICAL OPS OFFICER

    Shares
    2,464
    Price
    $90.25
    Value
    $222,376
  • Almstead Neil GregorySale

    7 Jul 2026, CHIEF TECHNICAL OPS OFFICER

    Shares
    24,613
    Price
    $88.89
    Value
    $2.19M
  • Boulding Mark ElliottSale

    6 Jul 2026, EXEC. VP AND CLO

    Shares
    4,478
    Price
    $84.90
    Value
    $380,203
  • Almstead Neil GregorySale

    6 Jul 2026, CHIEF TECHNICAL OPS OFFICER

    Shares
    22,161
    Price
    $86.00
    Value
    $1.91M
  • Almstead Neil GregorySale

    26 Jun 2026, CHIEF TECHNICAL OPS OFFICER

    Shares
    8,130
    Price
    $85.26
    Value
    $693,151
  • Almstead Neil GregorySale

    25 Jun 2026, CHIEF TECHNICAL OPS OFFICER

    Shares
    20,960
    Price
    $85.97
    Value
    $1.8M
  • Almstead Neil GregorySale

    24 Jun 2026, CHIEF TECHNICAL OPS OFFICER

    Shares
    5,323
    Price
    $85.03
    Value
    $452,607
  • Almstead Neil GregorySale

    22 Jun 2026, CHIEF TECHNICAL OPS OFFICER

    Shares
    23,749
    Price
    $80.90
    Value
    $1.92M
  • Utter Christine MarieSale

    17 Jun 2026, SVP, CHIEF ACCOUNTING OFFICER

    Shares
    19,686
    Price
    $75.56
    Value
    $1.49M
  • Boulding Mark ElliottSale

    17 Jun 2026, EXEC. VP AND CLO

    Shares
    10,462
    Price
    $78.65
    Value
    $822,868
  • Pauwels EricSale

    10 Jun 2026, CHIEF BUSINESS OFFICER

    Shares
    17,566
    Price
    $75.00
    Value
    $1.32M
  • Boulding Mark ElliottSale

    15 May 2026, EXEC. VP AND CLO

    Shares
    2,812
    Price
    $72.18
    Value
    $202,958
  • Klein Matthew B.Sale

    14 May 2026, CHIEF EXECUTIVE OFFICER

    Shares
    12,572
    Price
    $72.95
    Value
    $917,154

Partial trades from one filing are shown in one row, with the average price.

Source: Form 4 filings with the US Securities and Exchange Commission. Grants, option exercises, gifts and tax withholdings are hidden. Not a recommendation to buy.

What happened at PTC Therapeutics

The key events of the last six months from our own data. A click takes you to the matching card.

Sector comparison

714 rated companies in Healthcare

Rank 408 of 714
408/ 714
This company
48
Sector median
53

Categories against the sector median

ProfitabilityMedian of 714 companies38 (median 37)1 above the median
GrowthMedian of 714 companies70 (median 53)17 above the median
FundamentalsMedian of 714 companies24 (median 46)22 below the median
ValuationMedian of 477 companies with a value65 (median 54)11 above the median
StabilityMedian of 714 companies62 (median 67)5 below the median
Capital allocationMedian of 714 companies27 (median 39)12 below the median
Technical analysisMedian of 714 companies61 (median 70)9 below the median
MomentumMedian of 714 companies47 (median 71)24 below the median

The median is the middle value: half of the companies in the sector lie above it, half below. Categories with too few comparable companies are left out.

Competitors in Biotechnology

The next larger and next smaller companies by market value

All 296 Biotechnology stocks

ETFs that hold PTC Therapeutics

Held by 18 ETFs on Xetra. Shown per index: the ETF with the largest weight.

ETFWeightCostFund size
L&G Pharma Breakthrough UCITS ETFETLI2.46%0.49%€26.29M
Harbor Health Care UCITS ETF AccW3111.94%0.89%€11.61M
iShares Healthcare Innovation UCITS ETF2B780.53%0.40%€1.49B
Show 5 more
iShares Ageing Population UCITS ETF2B770.43%0.40%€807M
iShares Nasdaq US Biotechnology UCITS ETF2B700.36%0.35%€1.21B
iShares S&P SmallCap 600 UCITS ETFIUS30.32%0.30%€2.28B
L&G Russell 2000 US Small Cap Quality UCITS ETFETLZ0.29%0.30%€185.82M
Xtrackers Russell 2000 UCITS ETF 1CXRS20.18%0.30%€2.17B

Holdings as reported by the funds via FMP, excluding swap ETFs (their holdings are only collateral).

Data status and sources

Score
Daily value of 12 Nov 2026, recalculated nightly
Price
Closing price of 12 Nov 2026
Latest annual report
Fiscal year 2025, period end 31 Dec 2025
Source
Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Original filings at the SECReport a data error

Mandatory disclosures for this rating

  • ; time horizon around 12 months
  • Rated Weak, published since 7 Nov 2026 (in the score history since 8 May 2026)
  • Valuation signal Fairly valued since 7 Nov 2026
  • End-of-day prices, metrics cached for up to 24 hours
  • Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
  • Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
  • Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.
Full disclosures, methodology and data sourcesAll ratings of the last 12 monthsHow the score is calculated

MEQIRI counts visits without cookies. With your consent we remember for 90 days where you came from, also in your account, count page changes and time on page, recognise your next visit and load the Meta Pixel, which measures our advertising. You can withdraw your consent at any time under Cookie settings. Privacy